First Time Loading...
S

SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600

Watchlist Manager
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Watchlist
Price: 18.08 HKD -0.22%
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
SciClone Pharmaceuticals (Holdings) Ltd

Wall Street analysts forecast SciClone Pharmaceuticals (Holdings) Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SciClone Pharmaceuticals (Holdings) Ltd is 18.31 HKD with a low forecast of 18.08 HKD and a high forecast of 18.9 HKD.

Lowest Forecast
Wall Street Target
18.08 HKD
0% Downside
Average Forecast
Wall Street Target
18.31 HKD
1% Upside
Highest Forecast
Wall Street Target
18.9 HKD
5% Upside
Lowest
Price Target
18.08 HKD
0% Downside
Average
Price Target
18.31 HKD
1% Upside
Highest
Price Target
18.9 HKD
5% Upside
SciClone Pharmaceuticals (Holdings) Ltd Competitors:
Price Targets
008930
Hanmi Science Co Ltd
3% Downside
K
GUD
Knight Therapeutics Inc
16% Upside
SNDL
Sundial Growers Inc
57% Upside
4519
Chugai Pharmaceutical Co Ltd
23% Upside
008930
Hanmi Science Co Ltd
3% Downside
K
GUD
Knight Therapeutics Inc
16% Upside
SNDL
Sundial Growers Inc
57% Upside
4519
Chugai Pharmaceutical Co Ltd
23% Upside
300723
Yipinhong Pharmaceutical Co Ltd
47% Upside
VLS
Vita Life Sciences Ltd
62% Downside
T
TORNTPHARM
Torrent Pharmaceuticals Ltd
2% Downside
600750
Jiang Zhong Pharmaceutical Co Ltd
19% Upside

Revenue
Forecast

Revenue Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.

18%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 18%. The projected CAGR for the next 2 years is 10%.

18%
Past Growth
10%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 7%.

16%
Past Growth
7%
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SciClone Pharmaceuticals (Holdings) Ltd's stock price target?
Price Target
18.31 HKD

According to Wall Street analysts, the average 1-year price target for SciClone Pharmaceuticals (Holdings) Ltd is 18.31 HKD with a low forecast of 18.08 HKD and a high forecast of 18.9 HKD.

What is SciClone Pharmaceuticals (Holdings) Ltd's Revenue forecast?
Projected CAGR
16%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.

What is SciClone Pharmaceuticals (Holdings) Ltd's Operating Income forecast?
Projected CAGR
10%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 18%. The projected CAGR for the next 2 years is 10%.

What is SciClone Pharmaceuticals (Holdings) Ltd's Net Income forecast?
Projected CAGR
7%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 7%.

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.